Mitsubishi Tanabe Pharma Corporation

Norimitsu Hayashi

Osamu Sakurai

Hiroaki Sawamoto

Kunio Saruta

Yoshinori Nakamura

Hitoshi Kubota

Takanori Higashijima

Kenji Fukunaga

Masahiro Okuyama

Kozo Oka

Ritsuo Imashiro

Kenji Morokuma

Daisuke Iijima

Hiroaki Shitama

Hideki Horiuchi

Hidekazu Tsujishima

Takashi Goi

Eri Ooboki

Kenji Usui

Yoshikazu Mori

Masaki Okamoto

Akira Sakuragi

Takeshi Hamada

Nobuaki Fujimoto

Noriaki Itagaki

Eri Oboki

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Bicyclic heterocyclic compound

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CRor nitrogen atom; Ris hydrogen and the like; Ris alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Aromatic heterocyclic compound

The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group,

Bicyclic or tricyclic heterocyclic compound

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

The present invention is to provide a process for preparing optically active tetrahydroquinoline derivatives which can be used for the treatment and/or prevention of diseases such as arteriosclerotic diseases, dyslipidemia and the like, and a process for preparing synthetic intermediates thereof. Specifically, (2R,4S)-2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-ylamine or a salt thereof is prepared with fewer steps without using an optical resolution, and the optically active tetrahydroquinoline derivatives are obtained from the amine compound.

Process for preparing tetrahydroquinoline derivatives

The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; Ris an optionally substituted alkyl group, and the like; and Ris an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

Trisubstituted amine compound

Growing community of inventors

Osaka, Japan

Norimitsu Hayashi